The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Detailed price information for Cosciens Biopharma Inc (CSCI-T) from The Globe and Mail including charting and trades.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

QUESTION: Although it says right on the package of baking soda that you can use it for heartburn, if you choose to use it, ...

India’s pharmaceutical industry is projected to hit $42.9b by 2028 with a compound annual growth rate of 6.3% in local ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

The evolution of Pharma 4.0 integrates advanced technologies, transforming drug development and manufacturing with improved ...

To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to ...

and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking ...

Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion ...